Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sustainable Discovery and Development of Antibiotics

Literature DB >> 31216396

Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

Travis B Nielsen¹, Eric P Brass¹, David N Gilbert¹, John G Bartlett¹, Brad Spellberg¹.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
Anti-Bacterial Agents

Year: 2019 PMID： 31216396 PMCID： PMC6697094 DOI： 10.1056/NEJMp1905589

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

18 in total

1. Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.

Authors: Cornelius J Clancy; M Hong Nguyen
Journal: Antimicrob Agents Chemother Date: 2019-10-07 Impact factor: 5.191

2. The Economic Conundrum for Antibacterial Drugs.

Authors: David M Shlaes
Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191

3. Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.

Authors: Brad Spellberg; Travis B Nielsen; David N Gilbert; Andrew F Shorr; Eric P Brass
Journal: Ann Intern Med Date: 2019-10-08 Impact factor: 25.391

Review 4. Clinical Utility of Lefamulin: If Not Now, When?

Authors: Nicholas J Mercuro; Michael P Veve
Journal: Curr Infect Dis Rep Date: 2020-07-09 Impact factor: 3.725

5. Monoclonal Antibody Requires Immunomodulation for Efficacy Against Acinetobacter baumannii Infection.

Authors: Travis B Nielsen; Jun Yan; Brian M Luna; Yuli Talyansky; Matthew Slarve; Robert A Bonomo; Brad Spellberg
Journal: J Infect Dis Date: 2021-12-15 Impact factor: 7.759

Review 6. Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?

Authors: Piero Pollesello; Tuvia Ben Gal; Dominique Bettex; Vladimir Cerny; Josep Comin-Colet; Alexandr A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Veli-Pekka Harjola; Antoine Herpain; Matthias Heringlake; Leo Heunks; Trygve Husebye; Visnja Ivancan; Kristian Karason; Sundeep Kaul; Jacek Kubica; Alexandre Mebazaa; Henning Mølgaard; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Bojan Vrtovec; Mehmet B Yilmaz; Zoltan Papp
Journal: J Clin Med Date: 2019-11-01 Impact factor: 4.241

Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

1. Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.

2. The Economic Conundrum for Antibacterial Drugs.

3. Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.

Review 4. Clinical Utility of Lefamulin: If Not Now, When?

5. Monoclonal Antibody Requires Immunomodulation for Efficacy Against Acinetobacter baumannii Infection.

Review 6. Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?

7. Treatment of multidrug-resistant gram-negative bacilli after solid organ transplant: Outcomes and complications.

8. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.

Review 9. Antibiotics in the clinical pipeline in October 2019.

10. There is no market for new antibiotics: this allows an open approach to research and development.